I-Corps: Nano Drug Enabled Cancer Therapy

这个I-Corps项目的更广泛的影响/商业潜力是开发一个平台，以了解纳米颗粒的毒理学特性，并最终允许开发更好的乳腺癌治疗策略。这项工作将为进一步了解纳米颗粒在靶向特定癌症类型中的应用奠定基础，并了解致癌转化。根据体内模型中细胞对这些制剂的反应，这些研究具有转化潜力，并可能形成临床试验的基础。对于未来的研究，我们建议增加针对不同途径或同一途径的不同组分以及癌症的其他标志（如代谢重编程和免疫）的药物。此外，在我们的纳米平台中加入与恶性肿瘤相关的表观遗传变化的抑制剂将具有更大的商业应用。该项目将进行客户发现，以寻求产品的市场适应性，并进一步支持安全有效的癌症治疗应用策略的开发。该I-Corps项目基于开发新型纳米颗粒和癌细胞高度表达的抗原，以提供药物来抑制细胞增殖途径。该平台可以适用于治疗其他癌症类型，例如，胰腺癌所述纳米颗粒对靶向EpCAM或Her 2或两者的AuNR/Ag-雷帕霉素产生稳健的协同凋亡响应。该平台还使用FDA批准的雷帕霉素，开发减少毒副作用的纳米制剂。未来的研究将增加针对不同途径或相同途径的不同组分以及癌症的其他标志（如代谢重编程和免疫）的药物。此外，纳入与恶性肿瘤相关的表观遗传变化抑制剂将具有巨大的商业应用价值。该奖项反映了NSF的法定使命，并被认为值得通过使用基金会的知识价值和更广泛的影响审查标准进行评估来支持。

The broader impact/commercial potential of this I-Corps project is the development of a platform to understanding of the toxicological properties of nanoparticles and ultimately allow for the development of better therapeutic strategies for breast cancer treatment. This work will form a basis for further understanding of the use of nanoparticles in targeting specific cancer types and learn about oncogenic transformation. Depending upon cell response to these formulations in in vivo models, these studies have translational potential and might form basis for clinical trial. For future studies, we propose to add drugs that target different pathways or different components of the same pathway and other hallmarks of cancer such as metabolic reprogramming and immunity. Additionally, incorporating inhibitors of epigenetic changes linked to malignancies in our nano-platform would be of greater commercial application. This project will conduct customer discovery to seek product market fit and further support the development of strategies for safe and effective cancer treatment applications.This I-Corps project is based on the development of novel nanoparticles and antigens highly expressed on cancer cells to deliver drugs to inhibit cell proliferative pathway. This platform can be adapted to treat other cancer types, e.g., pancreatic cancer. The nanoparticles create a robust, synergistic apoptotic response to AuNRs/Ag-rapamycin targeting EpCAM or Her2, or both. The platform also uses FDA-approved, rapamycin, developing nano-formulations that reduce toxic side effects. Future studies will add drugs that target different pathways or different components of the same pathway and other hallmarks of cancer such as metabolic reprogramming and immunity. Additionally, incorporating inhibitors of epigenetic changes linked to malignancies would be of great commercial application.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.